

# Accepted Manuscript

Evaluation of waist-to-height ratio to predict 5 year cardiometabolic risk in sub-Saharan African adults

L.J. WARE, K.L. RENNIE, H.S. KRUGER, I.M. KRUGER, M. GREEFF, C.M.T. FOURIE, H.W. HUISMAN, J.D.W. SCHEEPERS, A.S. UYS, R. KRUGER, J.M. VAN ROOYEN, R. SCHUTTE, A.E. SCHUTTE

PII: S0939-4753(14)00074-X

DOI: [10.1016/j.numecd.2014.02.005](https://doi.org/10.1016/j.numecd.2014.02.005)

Reference: NUMECD 1253

To appear in: *Nutrition, Metabolism and Cardiovascular Diseases*


Received Date: 16 December 2013

Revised Date: 6 February 2014

Accepted Date: 11 February 2014

Please cite this article as: WARE L, RENNIE K, KRUGER H, KRUGER I, GREEFF M, FOURIE C, HUISMAN H, SCHEEPERS J, UYS A, KRUGER R, VAN ROOYEN J, SCHUTTE R, SCHUTTE A, Evaluation of waist-to-height ratio to predict 5 year cardiometabolic risk in sub-Saharan African adults, *Nutrition, Metabolism and Cardiovascular Diseases* (2014), doi: 10.1016/j.numecd.2014.02.005.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



- Obesity & CVD are increasing rapidly in Africa
- Low cost measures are needed to find those at risk
- Debate continues on the optimum Waist Circumference threshold for African adults.
- Waist-to-height ratio predicts current & future CVD risk in South-African adults.
- There is greater global agreement on the WHtR threshold ( $>0.5$ ) for risk.

ACCEPTED MANUSCRIPT

**Evaluation of waist-to-height ratio to predict 5 year cardiometabolic risk in sub-Saharan African adults**

WARE LJ<sup>a</sup>, RENNIE KL<sup>b</sup>, KRUGER HS<sup>c</sup>, KRUGER IM<sup>d</sup>, GREEFF M<sup>d</sup>, FOURIE CMT<sup>a</sup>, HUISMAN HW<sup>a</sup>, SCHEEPERS JDW<sup>a</sup>, UYS AS<sup>a</sup>, KRUGER R<sup>a</sup>, VAN ROOYEN JM<sup>a</sup>, SCHUTTE R<sup>a</sup>, SCHUTTE AE<sup>a</sup>.

<sup>a</sup>Hypertension in Africa Research Team (HART), Faculty of Health Sciences, North-West University, South Africa; <sup>b</sup>Centre for Lifespan and Chronic Illness Research, University of Hertfordshire, United Kingdom; <sup>c</sup>Centre of Excellence for Nutrition (CEN), Faculty of Health Sciences, North-West University, South Africa; <sup>d</sup>Africa Unit for Transdisciplinary Health Research (AUTHeR), Faculty of Health Sciences, North-West University, South Africa

Corresponding author: Aletta E Schutte, Hypertension in Africa Research Team, North-West University, Private Bag X6001, South Africa 2520 Telephone: +27 (0)18 299 2444, Facsimile: +27 (0)18 299 1053, E-mail: [Alta.Schutte@nwu.ac.za](mailto:Alta.Schutte@nwu.ac.za)

1 **Key Words:** Waist Circumference, Waist-to-height ratio, Cardiovascular disease,  
2 Hypertension, Diabetes, Dyslipidaemia, Risk factors, Sub-Saharan Africa, Adults.

3 **Word count:** Abstract - 250, Text – 3,183 (including authors and affiliations, corresponding  
4 author, abstract and acknowledgements).

5

6

7

8

9

10

## 1 ABSTRACT

### 2 Background and aims

3 Simple, low-cost central obesity measures may help identify individuals with increased  
4 cardiometabolic disease risk, although it is unclear which measures perform best in African  
5 adults. We aimed to: 1) cross-sectionally compare the accuracy of existing waist-to-height  
6 ratio (WHtR) and waist circumference (WC) thresholds to identify individuals with  
7 hypertension, pre-diabetes, or dyslipidaemia; 2) identify optimal WC and WHtR thresholds to  
8 detect CVD risk in this African population; and 3) assess which measure best predicts 5-year  
9 CVD risk.

### 10 Methods and results

11 Black South Africans (577 men, 942 women, aged > 30years) were recruited by random  
12 household selection from four North West Province communities. Demographic and  
13 anthropometric measures were taken. Recommended diagnostic thresholds (WC >80 cm for  
14 women, >94 cm for men; WHtR > 0.5) were evaluated to predict blood pressure, fasting  
15 blood glucose, lipids, and glycated haemoglobin measured at baseline and 5 year follow up.  
16 Women were significantly more overweight than men at baseline (mean body mass index  
17 (BMI) women  $27.3 \pm 7.4$  kg/m<sup>2</sup>, men  $20.9 \pm 4.3$  kg/m<sup>2</sup>; median WC women 81.9 cm  
18 (interquartile range 61–103), men 74.7 cm (63–87cm), all  $P < 0.001$ ). In women, both WC  
19 and WHtR significantly predicted all cardiometabolic risk factors after 5 years. In men, even  
20 after adjusting WC threshold based on ROC analysis, WHtR better predicted overall 5-year  
21 risk. Neither measure predicted hypertension in men.

### 22 Conclusions

23 The WHtR threshold of >0.5 appears to be more consistently supported and may provide a  
24 better predictor of future cardiometabolic risk in Sub-Saharan Africa.

1

**INTRODUCTION**

2 Some of the most rapid increases in obesity and the associated cardiometabolic disease are  
3 currently occurring in sub-Saharan Africa (SSA) (1, 2) creating a growing demand for  
4 suitable tools that can be employed to determine risk. Measures of central obesity, such as  
5 waist circumference (WC) and waist-to-height ratio (WHtR), are simple to collect,  
6 appropriate for low-resource settings, and better discriminators of cardiovascular disease  
7 (CVD) risk than body mass index (BMI)(3). However, it is unclear which markers of central  
8 obesity perform best in SSA adults to predict CVD.

9 Current recommended diagnostic thresholds for WC in Africa from the World Health  
10 Organisation (WHO;  $WC_{WHO} > 94$  cm for men,  $> 80$  cm for women) (4) are based  
11 predominantly on prospective analyses in Caucasian reference populations. However, recent  
12 evidence from cross-sectional studies in SSA would suggest that these may not be  
13 appropriate for African populations (5-10) and ethnicity specific thresholds (such as those  
14 recommended for Asian populations (4)) may be required. While the recommended WHtR  
15 threshold of 0.5 has largely been determined from Caucasian and Asian populations, (11, 12),  
16 this WHtR threshold requires validation in SSA populations.

17 The aims of this study were: 1) To compare the accuracy of existing WC and WHtR  
18 thresholds to cross-sectionally identify individuals with hypertension, pre-diabetes, or  
19 dyslipidaemia; 2) to determine the optimal WC and WHtR thresholds for detection of these  
20 CVD risk factors in an African population; and 3) to determine whether these thresholds  
21 prospectively predict 5-year CVD risk.

22

23

1

## 2 **METHODS**

### 3 **Study population**

4 The Prospective Urban Rural Epidemiology (PURE) study is a multinational cohort study  
5 examining the environmental, societal and biological determinants of obesity and chronic  
6 health problems. Study design, methodology, and specific recruitment procedures for PURE  
7 South Africa are described in detail elsewhere (13, 14). In brief, the first South African cohort  
8 began in 2005, with 5 year follow-up (2010). Black African men and women (n = 2010, age  
9 > 30 years, no previous HIV diagnosis) were recruited from 6000 randomly selected  
10 households in two urban (n = 1004, 60 % female) and two rural (n = 1006, 65 % female)  
11 North West Province communities. Trained fieldworkers speaking the participants' home  
12 languages (predominantly Setswana) were used and all participants provided written  
13 informed consent prior to taking part in the study. Participants were followed up in 2010. The  
14 study complied with the ethical principles for medical research involving human subjects as  
15 stated in the Declaration of Helsinki (15) and was approved by the North-West University  
16 Ethics Committee.

### 17 **Measurements**

18 Height (without shoes) was measured to the nearest 0.1 cm with a stadiometer (SECA,  
19 Hamburg Germany). Weight in light clothing was measured to the nearest 0.01 kg on  
20 portable electronic scales (A&D Medical, Abingdon UK). WC was measured midway  
21 between the iliac crest and the lower margin of the last palpable rib in the mid-axillary line  
22 using a steel anthropometric tape measure (Lufkin, Apex USA). BMI and WHtR were  
23 calculated using the formulae  $BMI = weight (kg)/height (m)^2$  and  $WHtR = WC (cm)/height$   
24  $(cm)$ , respectively.

1 Blood samples were drawn at the antecubital fossa following an overnight fast. Plasma  
2 glucose, serum high-density lipoprotein (HDL)-cholesterol and triglyceride concentrations  
3 were determined using two Sequential Multiple Analyser Computers (Cobas Integra 400 plus,  
4 Roche, Basel Switzerland; Konelab 20i, Thermo Scientific, Finland). Glycated haemoglobin  
5 (HbA1c) was analysed using the D-10 Hemoglobin Testing System (Bio-Rad Laboratories,  
6 Hercules USA). Human Immunodeficiency Virus (HIV) status was determined with the First  
7 Response (PMC Medical, Nani Daman India) rapid HIV card test using whole blood. If  
8 positive, the test was repeated with the Pareeshak (BHAT Bio-tech, Bangalore India) card  
9 test. Following 10 minutes rest, systolic (SBP) and diastolic blood pressure (DBP) were  
10 measured on the right upper arm using an automated monitor (HEM-757, Omron Healthcare,  
11 Tokyo Japan) and appropriate size cuff and participants seated with their arm supported at the  
12 level of the heart. A second BP measure taken after 5 minutes was used for analysis.

### 13 **Metabolic risk factor definitions**

14 The diagnostic criteria for elevated CVD risk were: hypertension (SBP  $\geq$  140 mmHg and/or  
15 DBP  $\geq$  90 mmHg or on antihypertensive treatment); low HDL-C ( $<$  1 mmol/l in men,  $<$  1.3  
16 mmol/l in women); elevated triglycerides (TG  $>$  1.7 mmol/l or 150 mg/dl); impaired fasting  
17 glucose (IFG  $>$  5.6 mmol/l or 100 mg/dl); elevated HbA1c with high risk of developing  
18 diabetes (HbA1c  $>$  6.0% or 42 mmol/mol) (WHO, International Society of Hypertension,  
19 International Diabetes Federation, American Heart Association and American Diabetes  
20 Association guidelines (16-20)).

### 21 **Statistical methods**

22 Statistical analyses were performed using Stata version 13 (StataCorp, Texas, USA).  
23 Participants that were pregnant ( $n = 13$ ), tested positive for HIV ( $n = 320$ ) or with missing  
24 data ( $n = 158$ ), were excluded from baseline analysis. Normality of variables was checked

1 with visual inspection of histogram plots and the Shapiro-Wilk test. Differences between men  
2 and women in the remaining baseline sample ( $n = 1,519$ ) were analysed by independent t-test  
3 for normally distributed data and the Mann-Whitney U test for non-normally distributed data  
4 for continuous variables. The Chi Square test was used for categorical variables. Analyses  
5 were considered statistically significant at  $P < 0.05$ . Receiver Operator Characteristic (ROC)  
6 curves and Youden's Index ( $J = \text{sensitivity} + \text{specificity} - 1$ ) were used to assess diagnostic  
7 test performance (21) and identify WC and WHtR thresholds predicting baseline metabolic  
8 risk in men and women separately. Poor measures with ROC area under the curve (AUC) <  
9 0.60 (22) were excluded.

10 At 5-year follow-up, 477 participants were lost to follow up (30 % had died, 26 % moved, 31  
11 % refused, 13 % unable to contact). Participants testing positive for HIV at follow-up ( $n =$   
12 59), pregnant ( $n = 6$ ), or with missing data were excluded leaving  $n = 917$  with complete  
13 data. Any participant classified with a baseline metabolic risk factor was excluded from  
14 subsequent prospective analyses for that risk factor. Logistic regression models were used to  
15 estimate the odds of developing each metabolic risk factor in 2010 using the WC and WHtR  
16 diagnostic thresholds identified at baseline. Men and women were analysed separately  
17 adjusting for age, baseline smoking status, alcohol consumption and menopausal status  
18 (women only). Backwards selection procedure was used to select the covariates. Likelihood  
19 ratio tests were used to determine whether WC and WHtR diagnostic thresholds should be  
20 included in the logistic regression models. Odds ratios (ORs) and 95% confidence intervals  
21 (CIs) for each diagnostic threshold were computed for each metabolic risk factor from the  
22 multiple logistic regression models.

23

24

## 1 RESULTS

### 2 Participant characteristics

3 **Table 1** shows baseline characteristics of the participants (577 men, 942 women).

4 Employment levels were low and 78 % of all adults had either no education or were only  
5 educated until primary school level. Women had a higher BMI, WC and WHtR than men ( $P$   
6  $< 0.001$ ) and a more unfavourable metabolic profile (higher prevalence of IFG, elevated  
7 HbA1c, elevated triglycerides and low HDL-C). Prevalence of hypertension was above 50 %  
8 in both genders, although men displayed higher mean SBP ( $P < 0.001$ ) with higher use of  
9 tobacco (61% vs. 27%) and alcohol (60% vs. 28%). More women were on anti-hypertension  
10 medication (14 % vs. 6 %) than men, but median ‘on treatment’ SBP values suggest that BP  
11 management was not optimal in either group. Due to the gender differences observed, all  
12 subsequent analyses were conducted separately for men and women.

### 13 Cross-sectional analysis of WC, WHtR and cardiometabolic disease

14 Classification of participants as “at risk” by either  $WC_{WHO}$  (37 %,  $n = 555$ ) or by  $WHtR_{0.5}$  (44  
15 %,  $n = 674$ ) at baseline showed the two central obesity measures to not identify the same  
16 individuals. While most individuals with high WC also had high WHtR (97 % of women, 100  
17 % of men), there were , fewer individuals with a high WHtR and simultaneous high WC (92  
18 % of women and only 29% of men). More than 75 % of men with any of the metabolic risk  
19 factors had a waist circumference below the WHO threshold of 94 cm (**Table 2**). WHtR  
20 performed better to identify cases of risk in men although, with the exception of elevated  
21 triglycerides, over 50 % of men with an elevated risk factor also had a  $WHtR \leq 0.5$ . In  
22 contrast, both thresholds ( $WC_{WHO}$  and  $WHtR_{0.5}$ ) identified more than 65 % of women with  
23 elevated metabolic risk, with WHtR performing marginally better than WC for all CVD risk  
24 factors.

1 In men, there were no significant differences between WC and WHtR to identify risk of  
2 diabetes or dyslipidaemia but neither measure predicted hypertension (**Table 3**). In women,  
3 both WC and WHtR predicted all markers of metabolic risk, with a small but significant  
4 difference between WC and WHtR for low HDL-C ( $P=0.004$ ). ROC analysis confirmed the  
5 optimal threshold for WHtR to be the recommended threshold ( $>0.5$ ) in both men and  
6 women. In contrast, only the WHO WC recommendation for women ( $>80\text{cm}$ ) was supported  
7 by ROC analysis while the optimal WC threshold to predict risk in men was found to be 80  
8 cm (much lower than the WHO WC threshold of 94cm).

#### 9 **Prediction of 5 year metabolic risk development by WC and WHtR**

10 **Table 4** shows the OR (95 % CI) for 5-year metabolic risk by recommended and ROC  
11 identified optimal WC and WHtR thresholds in those with normal metabolic risk profile at  
12 baseline. Women with a WC $>80$  cm or WHtR $>0.5$  in 2005, had a significantly increased  
13 probability of developing all metabolic risk factors over 5 years after adjustment for age,  
14 smoking status, alcohol intake and menopausal status.

15 In men, the current recommended WHO threshold for waist circumference ( $> 94$  cm) showed  
16 the worst performance in predicting 5 year cardiometabolic risk. Reducing this WC threshold  
17 to  $> 80$  cm (WC<sub>PURE</sub>) resulted in the significant prediction of impaired fasting glucose, HDL-  
18 C, and triglycerides but not HbA1c or hypertension. While WHtR could also not predict  
19 hypertension in men, WHtR $>0.5$  was a significant predictor of all other metabolic risk factors  
20 over 5 years.

21

22

23

24

## 1 **DISCUSSION**

2 To our knowledge, this is the first prospective study to investigate which central obesity  
3 measures best predict future CVD risk in sub-Saharan African adults. The results suggest that  
4 WHtR<sub>0.5</sub> significantly and most consistently predicted 5-year cardiometabolic risk. The only  
5 exception was for the prediction of hypertension in men, where neither WC nor WHtR were  
6 able to predict the outcome. This may be in part due to high hypertension prevalence in this  
7 group (only 27% of men remained hypertension-free over 5 years). Similar hypertension  
8 prevalence between men and women despite differences in levels of obesity has previously  
9 been observed in South African populations (23) suggesting the relationship between obesity  
10 and hypertension development in men is confounded by other factors such as smoking and  
11 alcohol use, both significant in our logistic regression models. Alcohol intake in particular  
12 has previously been shown to be an important predictor of hypertension development in this  
13 group (24).

14 Identifying optimal WC thresholds for SSA adults is challenging without large, randomly  
15 selected cohorts and previous studies have recommended a number of different thresholds.  
16 One study in black South African teachers ( $n = 81$  men,  $n = 90$  women, aged 25–65 years)  
17 recommended higher WC thresholds (90–96 cm for men, 92–98 cm for women) (8). Another  
18 study of black South African mothers in Soweto ( $n = 1180$ , mean age  $40 \pm 10.6$  years, 50.1 %  
19 obese) also suggested the WC threshold should be higher at  $> 91.5$  cm, 90.1 cm and 87.6 cm  
20 to predict metabolic syndrome, elevated BP ( $> 135/85$  mmHg), and low HDL-C respectively  
21 (9). In both these studies, men and women had higher mean BMI and waist circumference  
22 measures than those observed in our current study, most likely contributing to the higher WC  
23 cut-point recommendations. Other studies present similar results to our own, with optimal  
24 thresholds for predicting elevated blood pressure (WC  $> 80$ -80.5 cm, WHtR  $> 0.53$ -0.57),

1 elevated fasting blood glucose ( $WC > 81.5$  cm,  $WHtR > 0.51$ ), and low HDL-C ( $WC > 77$   
2 cm,  $WHtR > 0.47$ ) reported for pre-menopausal black South African women and Ghanaian  
3 women (6, 10). However, previous studies are based on cross-sectional data and, even after  
4 optimising WC threshold based on our ROC analysis ( $WC_{PURE}$ ), WC could only predict 5  
5 year risk of three of the five cardiovascular risk factors in men.

6 While disagreement surrounds the optimal WC threshold for predicting metabolic risk in SSA  
7 adults, our confirmation of the optimal threshold for  $WHtR$  at  $> 0.5$  appears more  
8 consistently supported. Although limited studies have reported varied optimal  $WHtR$   
9 thresholds ranging from 0.45-0.65 (25-28), both meta-analysis and systematic reviews  
10 confirm the  $WHtR$  threshold of  $>0.5$  across Caucasian, Asian and Central American  
11 populations and indicate  $WHtR$  may be a better discriminator than WC or BMI for metabolic  
12 risk in adults, children, both genders and varying ethnic groups (3, 11, 12).  $WHtR$ , like WC,  
13 is cheap and easy to obtain, but can also be used with imperial or metric values, and use of  
14 the 0.5 threshold promotes a simple public health message “Keep your waist circumference to  
15 less than half your height”(29).

16 Limitations of this study are the generalizability of results to other populations in sub-  
17 Saharan Africa. As there are few prospective SSA population-based studies, this study both  
18 developed the thresholds in the cross-sectional data and then applied the thresholds  
19 prospectively in a sub-set of the population, who were free of the metabolic risk factor at  
20 baseline. Further application to other SSA prospective studies is needed to determine how  
21 well these thresholds predict long-term CVD risk. For this same reason, use of the lower WC  
22 threshold identified in men in this sample is not recommended and there is already great  
23 variability in the literature on an “optimal” WC threshold for identifying CVD risk. While  
24  $WHtR_{0.5}$  appears more consistently supported within and between countries, further large

1 prospective studies are required in SSA. Our sample did have higher unemployment rates  
2 than those reported for the province generally (45 %;(30)) possibly indicating a bias with  
3 employed persons being less available during the working week to participate in the study.  
4 Although it could be argued this population (low levels of employment; very little education)  
5 are those most vulnerable and in need of simple measures that can be used in targeting  
6 interventions to reduce non-communicable disease. A further limitation of the results is the  
7 exclusion of participants living with HIV as this does not present a real evaluation of sub-  
8 Saharan African populations. However, previous cross-sectional analysis of central obesity  
9 and CVD risk in this population including those living with HIV supports our findings (31).  
10 Furthermore, no adjustment was made for physical activity and dietary factors. These may  
11 also be important risk factors for CVD in this population. However, as the exposure of  
12 interest was the central obesity measure, we did not include physical inactivity and dietary  
13 factors in the models as they are major contributors to energy imbalance and thus central  
14 obesity.

15 Incorporating height into an assessment of central obesity may confer additional information  
16 about risk. Previous studies have determined a strong independent association between height  
17 and stroke risk (32), and coronary heart disease (33) whereby increased height appears  
18 protective. More recently, growth and timing of peak height velocity have also been  
19 associated with adult cardiovascular disease mortality (34). While these findings have yet to  
20 be confirmed in SSA, they may imply that adjusting central obesity measures for height  
21 provides a better indicator of the dynamic biopsychosocial factors involved in the relationship  
22 between body composition and cardiovascular risk than, for example, ethnicity adjusted WC  
23 cut-points, especially in countries undergoing rapid urbanisation and socioeconomic

1 transition. Incorporating height into the central obesity assessment may also be likely to  
2 reduce the variability observed between populations due to differences in height.

3

#### 4 **Conclusions**

5 Our findings from this large cohort study investigating the prospective association between  
6 WC, WHtR and the development of metabolic risk support the use of the recommended  
7 single waist-to-height ratio threshold of 0.5 to predict the development of cardiometabolic  
8 disease in sub-Saharan African men and women. In comparison to waist circumference  
9 measures, waist-to-height ratio ( $>0.5$ ) appears more consistently supported to detect  
10 cardiovascular risk across populations on the African continent.

11

12

#### 13 **ACKNOWLEDGEMENTS**

14 The authors would like to thank supporting staff and participants of the PURE study, in  
15 particular:

- 16 1. PURE-South Africa: The PURE-NWP-SA research team, fieldworkers and office staff in
- 17 AUTHeR, HART, and Dr Wayne Towers of CEN, North-West University, South Africa. 2.
- 18 PURE International: Dr S Yusuf and the PURE project office staff at the Population Health
- 19 Research Institute, Hamilton Health Sciences and McMaster University, ON, Canada.
- 20 3. Professor A Olckers and the Profiles of Resistance to Insulin in Multiple Ethnicities and
- 21 Regions (PRIMER) research team.

Disclaimer: The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the National Research Foundation or other

funding bodies. Any opinion, findings, and conclusions or recommendations expressed in this material are those of the author(s) and therefore the NRF do not accept any liability in regard thereto. Dr Alta Schutte takes responsibility for the contents of this article.

Sources of Support: The South Africa-Netherlands Research Programme on Alternatives in Development, South African National Research Foundation [GUN numbers 2069319 and FA2006040700010]; North West University; Population Health Research Institute; and the South African Medical Research Council. The funding sources had no involvement in the conduct of the research or preparation of the article.

1

2 The authors' contributions were as follows – IMK and MG designed research; HSK, IMK,  
3 CMTF, MG, HH, JMVR, JDWS, RS, ASU, AES and RK conducted research; KR performed  
4 statistical analysis; LW, KR, AES and RS wrote the paper; AES had primary responsibility  
5 for final content. All authors read and approved the final manuscript. None of the authors had  
6 any conflict of interest to declare.

## REFERENCES

- 1 1. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in  
2 developing countries. *Nutrition Reviews* 2012;70(1):3-21. doi: 10.1111/j.1753-  
3 4887.2011.00456.x.
- 4 2. Kengne AP, Echouffo-Tcheugui J-B, Sobngwi E, Mbanya J-C. New insights on diabetes  
5 mellitus and obesity in Africa—Part 1: prevalence, pathogenesis and comorbidities. *Heart*  
6 2013;99(14):979-83. doi: 10.1136/heartjnl-2012-303316.
- 7 3. Lee CM, Huxley RR, Wildman RP, Woodward M. Indices of abdominal obesity are better  
8 discriminators of cardiovascular risk factors than BMI: a meta-analysis. *J Clin Epidemiol*  
9 2008;61(7):646-53. doi: 10.1016/j.jclinepi.2007.08.012.
- 10 4. World Health Organization. *Waist Circumference and Waist-Hip Ratio: Report of a WHO*  
11 *Expert Consultation*. Geneva. 2008.
- 12 5. Motala AA, Esterhuizen T, Pirie FJ, Omar MA. The prevalence of metabolic syndrome and  
13 determination of the optimal waist circumference cutoff points in a rural South African  
14 community. *Diabetes Care* 2011;34(4):1032-7. doi: 10.2337/dc10-1921.
- 15 6. Evans J, Micklesfield L, Jennings C, Levitt NS, Lambert EV, Olsson T, Goedecke JH. Diagnostic  
16 ability of obesity measures to identify metabolic risk factors in South African women. *Metab*  
17 *Syndr Relat Disord* 2011;9(5):353-60. doi: 10.1089/met.2011.0034.
- 18 7. Schutte AE, Olckers A. Metabolic syndrome risk in black South African women compared to  
19 Caucasian women. *Horm Metab Res* 2007;39(9):651-7. doi: 10.1055/s-2007-985394.
- 20 8. Prinsloo J, Malan L, de Ridder JH, Potgieter JC, Steyn HS. Determining the waist  
21 circumference cut off which best predicts the metabolic syndrome components in urban  
22 Africans: the SABPA study. *Exp Clin Endocrinol Diabetes* 2011;119(10):599-603. doi:  
23 10.1055/s-0031-1280801.
- 24 9. Crowther NJ, Norris SA. The current waist circumference cut point used for the diagnosis of  
25 metabolic syndrome in sub-Saharan African women is not appropriate. *PLoS One*  
26 2012;7(11):e48883. doi: 10.1371/journal.pone.0048883
- 27 10. Arthur FK, Adu-Frimpong M, Osei-Yeboah J, Mensah FO, Owusu L. Prediction of metabolic  
28 syndrome among postmenopausal Ghanaian women using obesity and atherogenic markers.  
29 *Lipids Health Dis* 2012;11:101. doi: 10.1186/1476-511X-11-101
- 30 11. Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist  
31 circumference and BMI for adult cardiometabolic risk factors: systematic review and meta-  
32 analysis. *Obes Rev* 2012;13(3):275-86. doi: 10.1111/j.1467-789X.2011.00952.x.
- 33 12. Browning LM, Hsieh SD, Ashwell M. A systematic review of waist-to-height ratio as a  
34 screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a  
35 suitable global boundary value. *Nutr Res Rev* 2010;23(2):247-69. doi:  
36 10.1017/S0954422410000144.
- 37 13. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R,  
38 Avezum A, et al. Use of secondary prevention drugs for cardiovascular disease in the  
39 community in high-income, middle-income, and low-income countries (the PURE Study): a  
40 prospective epidemiological survey. *The Lancet* 2011;378(9798):1231-43. doi:  
41 10.1016/S0140-6736(11)61215-4.
- 42 14. Kruger A, LekalakalaMokgela SE, Wentzel-Viljoen E. Rural and urban older African caregivers  
43 coping with HIV/AIDS are nutritionally compromised. *Journal of Nutrition in Gerontology and*  
44 *Geriatrics* 2011;30(3):274-90. doi: 10.1080/01639366.2010.528333.
- 45 15. World Medical Association Declaration of Helsinki: ethical principles for medical research  
46 involving human subjects. *Bulletin of the World Health Organization* 2001;79(4):373-4.

- 1 16. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James  
2 WPT, Loria CM, Smith SC. Harmonizing the Metabolic Syndrome: A Joint Interim Statement  
3 of the International Diabetes Federation Task Force on Epidemiology and Prevention;  
4 National Heart, Lung, and Blood Institute; American Heart Association; World Heart  
5 Federation; International Atherosclerosis Society; and International Association for the Study  
6 of Obesity. *Circulation* 2009;120(16):1640-5. doi: 10.1161/circulationaha.109.192644.
- 7 17. Genuth S, Alberti K, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler W, Lebovitz  
8 H, Lernmark A. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*  
9 2003;26(11):3160.
- 10 18. World Health Organization. Prevention of Cardiovascular Disease: Guidelines for assessment  
11 and management of cardiovascular risk. Geneva. 2007.
- 12 19. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of  
13 Diabetes Mellitus. Geneva. 2011.
- 14 20. Standards of Medical Care in Diabetes - 2012. *Diabetes Care*;35(Supplement 1):S11-S63. doi:  
15 10.2337/dc12-s011.
- 16 21. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;3(1):32-5. doi: 10.1002/1097-  
17 0142(1950)3:1<32::aid-cnrc2820030106>3.0.co;2-3.
- 18 22. Glaser AN. High-yield biostatistics, epidemiology and public health. 4th ed. Philadelphia, USA:  
19 Lippincott, Williams & Wilkins, 2013.
- 20 23. Thorogood M, Connor M, Tollman S, Lewando Hundt G, Fowkes G, Marsh J. A cross-sectional  
21 study of vascular risk factors in a rural South African population: data from the Southern  
22 African Stroke Prevention Initiative (SASPI). *BMC Public Health* 2007;7:326. doi:  
23 10.1186/1471-2458-7-326.
- 24 24. Schutte AE, Schutte R, Huisman HW, van Rooyen JM, Fourie CM, Malan NT, Malan L, Mels  
25 CM, Smith W, Moss SJ, et al. Are behavioural risk factors to be blamed for the conversion  
26 from optimal blood pressure to hypertensive status in Black South Africans? A 5-year  
27 prospective study. *Int J Epidemiol* 2012;41(4):1114-23. doi: 10.1093/ije/dys106.
- 28 25. Lin WY, Lee LT, Chen CY, Lo H, Hsia HH, Liu IL, et al. Optimal cut-off values for obesity: using  
29 simple anthropometric indices to predict cardiovascular risk factors in Taiwan. *International*  
30 *journal of obesity and related metabolic disorders : journal of the International Association*  
31 *for the Study of Obesity*. 2002;26(9):1232-8.
- 32 26. Mirmiran P, Esmailzadeh A, Azizi F. Detection of cardiovascular risk factors by  
33 anthropometric measures in Tehranian adults: receiver operating characteristic (ROC) curve  
34 analysis. *Eur J Clin Nutr*.58(8):1110-8.
- 35 27. Hadaegh F, Zabetian A, Sarbakhsh P, Khalili D, James WPT, Azizi F. Appropriate cutoff values  
36 of anthropometric variables to predict cardiovascular outcomes: 7.6 years follow-up in an  
37 Iranian population. *Int J Obes*. 2009;33(12):1437-45.
- 38 28. Craig P, Colagiuri S, Hussain Z, Palu T. Identifying cut-points in anthropometric indexes for  
39 predicting previously undiagnosed diabetes and cardiovascular risk factors in the Tongan  
40 population. *Obesity Research & Clinical Practice*. 2007;1(1):17-25.
- 41 29. Ashwell M. The waist-to height ratio is a good, simple screening tool for cardiometabolic  
42 risk. *Nutrition Today* 2011;46(2):85-9. doi: 10.1097/NT.0b013e3182118779
- 43 30. South African Institute of Race Relations. Fast Facts January 2013. Internet:  
44 [http://www.sairr.org.za/services/publications/fast-facts/fast-facts-](http://www.sairr.org.za/services/publications/fast-facts/fast-facts-2013/files/January_Fast_Facts_2013.pdf/view)  
45 [2013/files/January\\_Fast\\_Facts\\_2013.pdf/view](http://www.sairr.org.za/services/publications/fast-facts/fast-facts-2013/files/January_Fast_Facts_2013.pdf/view) (accessed 01 October 2013).
- 46 31. Beneke J. Unpublished results. Anthropometrical indicators of non-communicable diseases  
47 for a black South African population in transition 2009 (Doctoral dissertation) North West  
48 University, Faculty Health Sciences: School of Biokinetics, Recreation and Sport Science.

- 1 32. Njølstad I, Arnesen E, Lund-Larsen PG. Body height, cardiovascular risk factors, and risk of  
2 stroke in middle-aged men and women a 14-year follow-up of the Finnmark study.  
3 *Circulation* 1996;94(11):2877-82. doi: 10.1161/01.CIR.94.11.2877  
4 33. Hebert PR, Rich-Edwards JW, Manson J, Ridker PM, Cook NR, O'Connor GT, Buring JE,  
5 Hennekens CH. Height and incidence of cardiovascular disease in male physicians.  
6 *Circulation* 1993;88(4):1437-43. doi: 10.1161/01.CIR.88.4.1437.  
7 34. Imai CM, Gunnarsdottir I, Gudnason V, Aspelund T, Birgisdottir BE, Thorsdottir I, Halldorsson  
8 TI. Early peak height velocity and cardiovascular disease mortality among Icelandic women.  
9 *Annals of Medicine*;45(8):545-50.  
10

**TABLE 1**Baseline characteristics of the study group (n=1,519) by gender <sup>1</sup>

	Men	Women	<i>P</i>
<i>n</i> (%)	577 (38)	942 (62)	
Age in years	51.2 ± 10.5	50.7 ± 10.3	0.4
Weight in kg	58.6 ± 12.6	67.0 ± 18.6	<0.001
Height in cm	167.3 ± 7.0	156.5 ± 6.4	<0.001
BMI in kg/m <sup>2</sup>	20.9 ± 4.3	27.3 ± 7.4	<0.001
Waist circumference in cm, median (IQR)	74.7 (12.3)	81.9 (20.6)	<0.001
Waist-to-Height Ratio	0.46 ± 0.006	0.53 ± 0.09	<0.001
Smokers, <i>n</i> (%)	350 (61)	440 (47)	<0.001
Alcohol consumers, <i>n</i> (%)	344 (60)	260 (28)	<0.001
In employment, <i>n</i> (%)	64 (12)	78 (9)	0.07
Educated to primary school or less, <i>n</i> (%)	448 (77.6)	735 (78)	0.862
Resident in rural community, <i>n</i> (%)	264 (46)	489 (52)	0.02
Cardiovascular measures, median (IQR)			
Systolic blood pressure in mmHg <sup>*</sup>	133.5 (29)	128.0 (31)	<0.001
Diastolic blood pressure in mmHg <sup>*</sup>	86.0 (19.5)	87.0 (18.0)	0.2829
Fasting blood glucose in mmol/l <sup>†</sup>	4.8 (1.0)	4.9 (1.0)	0.0038
HbA1c % (mmol/mol <sup>‡</sup> )	5.5 (0.5); 37 (5.5)	5.6 (0.6); 38 (6.6)	<0.001
Total triglyceride in mmol/l <sup>‡</sup>	0.97 (0.64)	1.15 (0.82)	<0.001
HDL cholesterol in mmol/l <sup>‡</sup>	1.55 (0.89)	1.44 (0.73)	0.001
Medication use, <i>n</i> (%)			
Diabetes medication	3 (0.5)	15 (1.6)	
Hypertension medication	37 (6.4)	127 (13.5)	
On treatment SBP in mmHg median (IQR)	143 (110-176)	140 (104-176)	
On treatment DBP in mmHg median (IQR)	90 (72-108)	93 (76-110)	
Metabolic risk factors, <i>n</i> (%)			
Hypertension (SBP ≥140 and/or DBP ≥90 mmHg)	297 (52)	511 (54)	0.293
Impaired fasting glucose (>5.6 mmol/l)	109 (19)	227 (24)	0.018
Elevated HbA1c (>6%, >42 mmol/l)	74 (13)	234 (25)	<0.001
Elevated triglyceride (>1.7 mmol/l)	84 (15)	222 (24)	<0.001
Low HDL-C (men<1.0 mmol/l, women<1.3 mmol/l)	90 (16)	372 (40)	<0.001

<sup>1</sup> Data are presented as means ±SD unless otherwise indicated, IQR is interquartile range.

*P* values are for comparison between men and women.

Excluding those on antihypertensive medication<sup>\*</sup>, medication for type 2 diabetes<sup>†</sup>, or cholesterol lowering medication<sup>‡</sup>.

**TABLE 2**

Distribution of cardiovascular disease risk factors in relation to recommended diagnostic thresholds for waist circumference and waist-to-height ratio<sup>2</sup>

Measure of central obesity:	<i>Cardiovascular disease risk factors</i>				
	Hypertension	Elevated triglyceride	Low HDL-C	Impaired fasting glucose	Elevated HbA1c
<i>n</i> (% of total cases)					
<i>Men (n=577)</i>					
Waist Circumference					
WHO					
≤94 cm (n=542)	271 (91%)	65 (77%)	75 (83%)	94 (86%)	59 (80%)
>94 cm (n=35)	26 (9%)	19 (23%)	15 (17%)	15 (14%)	15 (20%)
Waist-to-height ratio					
≤0.5 (n=454)	215 (72%)	34 (40%)	54 (60%)	67 (62%)	38 (51%)
>0.5 (n=123)	82 (28%)	50 (60%)	36 (40%)	42 (39%)	36 (49%)
<i>Women (n=942)</i>					
Waist Circumference					
WHO					
≤80 cm (n=422)	181 (35%)	60 (27%)	121 (32%)	75 (33%)	55 (24%)
>80 cm (n=520)	330 (65%)	162 (73%)	251 (68%)	152 (67%)	179 (76%)
Waist-to-height ratio					
≤0.5 (n=391)	156 (30%)	54 (24%)	117 (31%)	68 (30%)	51 (22%)
>0.5 (n=551)	355 (70%)	168 (76%)	255 (69%)	159 (70%)	183 (78%)

<sup>2</sup> WHO, World Health Organization; HDL-C, high density lipoprotein cholesterol; HbA1c, glycated haemoglobin

**TABLE 3**Waist circumference and waist-to-height ratio thresholds for metabolic risk variables in black South African men and women<sup>3</sup>

Men (n=577)							Women (n=942)								
ROC		P value		Optimal threshold	Optimal sensitivity (%)	Optimal specificity (%)	Youden J Value*	ROC		P value		Optimal Threshold	Optimal sensitivity (%)	Optimal specificity (%)	Youden J Value*
AUC	95% CI	(vs. WC)						AUC	95% CI	(vs. WC)					
Hypertension (SBP $\geq$ 140 or DBP $\geq$ 90 mmHg or taking antihypertensive medication)															
WC (cm)	<0.6 <sup>†</sup>							0.64	0.60-0.67			78.5	68.9	53.1	0.2202
WHtR	<0.6 <sup>†</sup>							0.64	0.60-0.67	0.63		0.51	67.7	56.8	0.2456
Elevated Triglycerides ( $\geq$ 1.7 mmol/l) or on triglyceride lowering medication															
WC (cm)	0.79	0.73-0.84		78.5	76.2	73.0	0.492	0.66	0.62-0.70			78.6	77.0	47.2	0.2425
WHtR	0.78	0.73-0.83	0.53	0.5	59.5	86.0	0.455	0.66	0.62-0.70	0.65		0.52	68.0	56.4	0.2441
Low HDL-C (<1.0 mmol/l in males; <1.3 mmol/l in females)															
WC (cm)	0.66	0.59-0.73		81.3	53.3	77.4	0.3075	0.63	0.60-0.67			81	65.6	55.8	0.2138
WHtR	0.66	0.59-0.72	0.84	0.48	52.2	75.8	0.2799	0.62	0.58-0.66	0.004		0.53	59.1	59.8	0.1896
Impaired Fasting Blood Glucose (>5.5 mmol/l) or taking glucose-lowering medication															
WC (cm)	0.63	0.57-0.69		78.5	53.2	70.3	0.235	0.62	0.58-0.66			84.3	59.5	62.0	0.2143
WHtR	0.63	0.56-0.69	0.73	0.51	36.7	86.1	0.228	0.62	0.58-0.66	0.71		0.52	65.6	55.3	0.2088
Elevated HbA1c (>6%) or taking glucose-lowering medication															
WC (cm)	0.66	0.59-0.74		79.6	58.1	72.4	0.305	0.71	0.67-0.74			85.7	63.7	69.5	0.3317
WHtR	0.64	0.56-0.72	0.12	0.5	48.7	83.9	0.326	0.71	0.67-0.75	0.22		0.56	61.5	72.7	0.3428

<sup>3</sup> \*J=(sensitivity + specificity) - 1. <sup>†</sup>ROC AUC<0.6, data not shown. ROC, receiver operated characteristic; AUC, area under the curve; CI, confidence interval; WC, waist circumference; WHtR, waist to height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high density lipoprotein cholesterol; HbA1c, glycated haemoglobin

**TABLE 4**Prediction of 5 year metabolic risk using waist circumference and waist-to-height ratio in black South African men and women<sup>4</sup>

	<i>WC<sub>WHO</sub></i>		<i>WHR<sub>0.5</sub></i>		<i>WC<sub>PURE</sub> (Men only)</i>	
	<i>OR (95% CI)</i>	<i>P-value</i>	<i>OR (95% CI)</i>	<i>P-value</i>	<i>OR (95% CI)</i>	<i>P-value</i>
Hypertension (SBP $\geq$ 140 or DBP $\geq$ 90 mmHg or taking antihypertensive medication)						
Men ( <i>n</i> =155)	†	†	†	†	†	†
Women ( <i>n</i> =251)	2.3 (1.4, 4.0)	0.002	2.0 (1.2, 3.4)	0.011	-	
Elevated Triglycerides ( $\geq$ 1.7 mmol/l) or on triglyceride lowering medication						
Men ( <i>n</i> =278)	4.1 (0.9, 18.9)	0.07	3.8 (1.5, 9.2)	0.004	3.0 (1.3, 6.8)	0.01
Women ( <i>n</i> =412)	2.3 (1.3, 4.1)	0.006	2.2 (1.2, 4.0)	0.009	-	
Low HDL-C (<1.0 mmol/L in males; <1.3 mmol/l in females)						
Men ( <i>n</i> =277)	4.0 (1.2, 14.0)	0.029	2.9 (1.3, 6.5)	0.009	2.6 (1.2, 5.7)	0.016
Women ( <i>n</i> =348)	4.0 (2.4, 6.6)	<0.001	3.5 (2.1, 5.8)	<0.001	-	
Impaired Fasting Blood Glucose (>5.5 mmol/l) or previous diagnosis Diabetes						
Men ( <i>n</i> =263)	†	†	3.6 (1.4, 9.4)	0.01	3.8 (1.5, 10.2)	0.007
Women ( <i>n</i> =423)	1.9 (1.1, 3.2)	0.025	2.2 (1.2, 3.9)	0.006	-	
Elevated HbA1c (>6%)						
Men ( <i>n</i> =286)	†	†	2.1 (1.1, 4.2)	0.031	1.5 (0.8, 2.9)	0.181
Women ( <i>n</i> =408)	1.7 (1.1, 2.6)	0.01	2.0 (1.3, 3.0)	0.001	-	

<sup>4</sup> NS, No significant contribution to the model (likelihood ratio test); †ROC AUC<0.6. All models adjusted for age (years), current smoking status, reported alcohol intake (and menopausal status in women). WCWHO – women >80 cm, men >94 cm; WCPURE – men >80 cm (taken from ROC AUC analysis in this African population from the PURE study).